CLDX Stock Risk & Deep Value Analysis

Celldex Therapeutics Inc

DVR Score

8.0

out of 10

Hidden Gem

What You Need to Know About CLDX Stock

We analyzed Celldex Therapeutics Inc using our deep value framework. Sign in to see our full verdict and DVR Score.

We ran CLDX through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.

Updated Apr 22, 2026•Run Fresh Analysis →

CLDX Risk Analysis & Red Flags

What Could Go Wrong

The biggest risk is a failure of barzolvolimab in its ongoing Phase 3 trials or a significant delay in regulatory approval. The company is largely a single-asset play; any major setback to barzolvolimab's development or commercialization could lead to a severe stock price decline of 50-80% or more, as the market's current valuation is heavily tied to its success.

Risk Matrix

Overall

Aggressive

Financial

Medium

Market

Medium

Competitive

Medium

Execution

Medium

Regulatory

High

Red Flags

⚠
Significant share dilution (~11.9M shares) from recent offering, though common for pre-commercial biotech funding.
⚠
JPMorgan Chase & Co. reduced its stake by 21% (49,046 shares) in the last 90 days, indicating some portfolio rebalancing.
⚠
Absence of profitability and free cash flow generation, typical for clinical-stage biotech but a persistent financial risk until commercialization.

Upcoming Risk Events

📅
Negative or inconclusive results from barzolvolimab Phase 3 trials
📅
Regulatory delays or outright rejection by the FDA
📅
Increased competitive pressure from new treatments for CSU/CIU

When to Reconsider

🚪
Failure of barzolvolimab to meet primary endpoints in Phase 3 trials.
🚪
Regulatory complete response letter (CRL) from FDA for barzolvolimab without clear path to approval.
🚪
Significant competitive entry (e.g., highly effective novel mechanism of action) into the CSU/CIU market.
🚪
Cash burn rate significantly exceeding projections without corresponding R&D progress or revenue prospects.

Unlock CLDX Risk Analysis & Red Flags

Create a free account to see the full analysis

Investment Thesis

Celldex is a high-conviction play on the successful approval and commercialization of barzolvolimab, a differentiated therapeutic for chronic urticaria with multi-billion dollar peak sales potential. The recent capital raise provides financial stability, and positive analyst sentiment alongside strong trial enrollment progress signals increasing confidence in the asset's success. The company holds a strong strategic position to capture significant market share in a lucrative and underserved therapeutic area, offering a pathway to 10x growth within the next 3-5 years if key milestones are met.

Is CLDX Stock Undervalued?

Celldex Therapeutics presents a compelling high-risk, high-reward opportunity, largely driven by its lead asset, barzolvolimab, currently in Phase 3 trials for chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIU). Analyst upgrades and strong enrollment progress indicate increasing confidence in this asset's multi-billion dollar peak sales potential, which could drive significant market cap expansion well beyond current levels. The recent $345M capital raise provides a strong cash runway for commercialization, significantly de-risking financial health. While currently unprofitable, typical for clinical-stage biotech, successful commercialization of barzolvolimab is the primary catalyst for a 10x return within 3-5 years. Dilution from the recent offering is a short-term headwind, but necessary for funding future growth and market leadership in its therapeutic areas. The absence of material negative news reinforces the positive outlook on its core development.

Unlock the full AI analysis for CLDX

Get the complete DVR score, risk analysis, and more

📈

Unlock the full report

Create a free account to see the DVR score, risk flags, and AI analysis.

CLDX Price Targets & Strategy

12-Month Target

$52.00

Bull Case

$75.00

Bear Case

$25.00

Valuation Basis

Based on a conservative 3x probability-weighted peak sales multiple (~$1.6B post-Barclays upgrade) for lead asset barzolvolimab, divided by fully diluted shares post-offering (~90.4M shares).

Entry Strategy

Consider dollar-cost averaging between $30-$35, especially on any dips following market volatility. The $29 (recent offering price) could act as a strong psychological support zone.

Exit Strategy

Take 25-50% profit at $65-$75 (approaching 2x current price, reflecting significant clinical de-risking and market re-rating). Set a trailing stop-loss or consider exiting below $29 if key clinical milestones are missed or if major negative data emerges.

Portfolio Allocation

5% for aggressive risk tolerance, reflecting the high-risk, high-reward nature of a clinical-stage biotech dependent on single-asset success.

Price Targets & Strategy

Upgrade to Premium for price targets and entry/exit strategies

Is CLDX Financially Healthy?

Valuation

P/E Ratio

-8.91

Forward P/E

-13.77

Profitability

Gross Margin

17.65%

Operating Margin

-13825.94%

Net Margin

-12400.58%

Return on Equity

-41.67%

Revenue Growth

-77.98%

EPS

$-3.90

Balance Sheet

Current Ratio

10.49

Quick Ratio

10.21

Other

Beta (Volatility)

1.01

Does CLDX Have a Competitive Moat?

Moat Rating

🛡️ Narrow

Moat Trend

Expanding

Moat Sources

2 Identified

Intangible Assets/IP (patent protection for barzolvolimab)Switching Costs (patients on an effective, well-tolerated therapy are less likely to switch)

The moat is driven by the patent protection and clinical differentiation of barzolvolimab. If successfully approved and commercialized, its unique mechanism and potential efficacy could establish it as a preferred treatment, creating significant switching costs for patients and prescribers. This durability is contingent on successful trials and market acceptance, and the strength of its IP over the next 10-15 years.

Moat Erosion Risks

•Expiry of key patents for barzolvolimab without further pipeline development or label expansion.
•Emergence of superior or equally effective competing therapies with better safety profiles or administrative convenience.
•Failure to achieve broad market adoption post-approval due to pricing, market access, or commercialization challenges.

CLDX Competitive Moat Analysis

CLDX Market Intelligence

Sentiment & Insider Activity

Social Sentiment

Bullish, driven by excitement around barzolvolimab's clinical progress and potential. Retail investors likely monitoring trial updates and approval timelines in online forums and social platforms.

Institutional Sentiment

Positive, evidenced by 'Strong Buy' analyst consensus and Barclays' upgrade to Overweight with a $45 PT. Goldman Sachs' Neutral rating with $34 PT suggests some tempered optimism, while JPMorgan's stake reduction indicates some portfolio rebalancing.

Insider Activity (Form 4)

JPMorgan Chase & Co. sold 49,046 shares (21% stake reduction) on or before April 3, 2026, leaving 184,775 shares valued at $4.78M. No specific individual insider buys/sells were reported in the provided data.

Options Flow

Normal options activity, with attention likely focused on May 14th earnings and upcoming clinical data catalysts. No unusual put/call ratio shifts were specifically noted in the provided research, suggesting no immediate institutional conviction via options beyond general market activity.

Earnings Intelligence

Next Earnings

2026-05-14

Surprise Probability

Medium

Historical Earnings Pattern

For clinical-stage biotechs, stock reactions to earnings are often driven by updates on pipeline progress and cash runway rather than traditional EPS/revenue beats. Positive clinical news tends to elicit strong rallies, while lack of progress or cash concerns can lead to sell-offs.

Key Metrics to Watch

Updates on barzolvolimab Phase 3 trial enrollment and progressCash runway and burn rate projections post-financingUpdates on other pipeline assetsForward guidance on R&D expenses and commercialization plans

Competitive Position

Top Competitor

N/A (No specific single 'best-in-class' direct peer for Barzolvolimab explicitly detailed in research. Broader competitors in chronic urticaria include established large pharma with drugs like Xolair, and other companies developing novel therapies for inflammatory diseases.)

Market Share Trend

Gaining. Barzolvolimab, if approved, would enter the chronic urticaria market, aiming to capture significant share from existing therapies and address unmet needs. Its novel mechanism of action (targeting KIT) provides a potential differentiator.

Valuation vs Peers

Difficult to provide a direct peer valuation comparison without specific listed peers. As a clinical-stage biotech, CLDX typically trades on pipeline potential and probability-adjusted peak sales rather than traditional profitability multiples, often at a premium to established, slower-growth pharma companies but potentially a discount to early-stage platform companies.

Competitive Advantages

•Novel mechanism of action (targeting KIT) for barzolvolimab, potentially offering superior efficacy/safety.
•Strong intellectual property protection for lead asset.
•Expedited Phase 3 enrollment progress, indicating efficient trial execution and potential market entry.

Market Intelligence

Get sentiment, earnings intel, and peer analysis with Premium

What Could Drive CLDX Stock Higher?

Near-Term (0-6 months)

•Q1 2026 Earnings Report (May 14, 2026), with potential clinical program updates
•Completion of barzolvolimab Phase 3 enrollment for CSU/CIU
•Presentation at upcoming medical conferences (e.g., dermatology, immunology)

Medium-Term (6-18 months)

•Top-line data readout from barzolvolimab Phase 3 trials
•Biologics License Application (BLA) submission to FDA for barzolvolimab
•Potential strategic partnerships for ex-US commercialization of barzolvolimab

Long-Term (18+ months)

•FDA approval and commercial launch of barzolvolimab in CSU/CIU
•Expansion of barzolvolimab into additional indications
•Advancement of other pipeline assets into later-stage clinical trials

Catalysts & Growth Drivers

Upgrade to Premium to see catalysts

What's the Bull Case for CLDX?

✓
Positive top-line data from barzolvolimab Phase 3 trials (primary driver).
✓
Successful and timely Biologics License Application (BLA) submission and FDA approval.
✓
Strong initial commercial launch metrics and market penetration post-approval.
✓
Continued progress of pipeline assets beyond barzolvolimab, diversifying future revenue streams.

Bull Case Analysis

See what could go right with Premium

📊 Explore More Stock Analysis

Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.

Analyze Any Stock →View Top 100 Deep Value Stocks →

How Celldex Therapeutics Inc Makes Money

Celldex Therapeutics is a clinical-stage biotechnology company focused on developing novel antibody-based therapeutics for the treatment of inflammatory diseases and cancer. Currently, its primary business model revolves around advancing its lead drug candidate, barzolvolimab, through late-stage clinical trials to regulatory approval. Upon successful approval, the company plans to generate revenue through the commercial sale of barzolvolimab, either independently or through partnerships, addressing significant unmet needs in chronic spontaneous urticaria and chronic inducible urticaria. The company aims to monetize its intellectual property through direct sales or licensing agreements, transitioning from a research and development phase to a commercial-stage biopharmaceutical enterprise.

Read Full Business Model Breakdown

FAQ

What is the DVR Score for Celldex Therapeutics Inc (CLDX)?

As of April 22, 2026, Celldex Therapeutics Inc has a DVR Score of 8.0 out of 10, placing it in the "Hidden Gem" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.

What is the market capitalization of Celldex Therapeutics Inc?

Celldex Therapeutics Inc's market capitalization is approximately $2.7B..

What is the risk level for CLDX stock?

Our analysis rates Celldex Therapeutics Inc's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.

What is the P/E ratio of CLDX?

Celldex Therapeutics Inc currently has a price-to-earnings (P/E) ratio of -8.9. This is below the market average, which could indicate the stock is undervalued or facing headwinds.

Is Celldex Therapeutics Inc's revenue growing?

Celldex Therapeutics Inc has reported revenue growth of -78.0%. Revenue has been declining, which warrants closer examination.

Is CLDX stock profitable?

Celldex Therapeutics Inc has a profit margin of -12400.6%. The company is currently unprofitable.

How often is the CLDX DVR analysis updated?

Our AI-powered analysis of Celldex Therapeutics Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on April 22, 2026.

Important Disclaimer – Not Financial Advice

Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for CLDX (Celldex Therapeutics Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.

All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.